Skin cancer: it's tough to hear, but you don't have to face it alone.
Our skin cancer team at Holden Comprehensive Cancer Center focus on every aspect of skin cancer—our clinicians are also top educators and researchers, and our team will walk you through everything from screening to follow-up care.
Skin cancer includes melanomas and non-melanoma skin cancers. The information on this page refers primarily to our non-melanoma skin cancer program. Find out more about our Melanoma Program.
Patients treated at NCI-designated cancer centers have better survival outcomes than patients treated at non–NCI-designated cancer centers, according to a recent study published in the journal Cancer. Holden Comprehensive Cancer Center at the University of Iowa is the only institution in Iowa to hold the prestigious designation of being a Comprehensive Cancer Center by the National Cancer Institute (NCI), meaning we are rated in the top 4 percent of the approximately 1,500 cancer centers in the United States.
To be considered a "comprehensive" center means our teams have expertise in clinical, laboratory, and population-based research. Our doctors and staff are on top of the newest developments in cancer research, treatment, and diagnosis.
Clinical trials is where research meets patient care. Clinical trials are research studies that test out the latest treatments and drugs that are not yet available to the wider public. These new treatments have the potential to improve your quality of life or increase your chances of survival.
Enrolling soon for melanoma: An exiting new study will be testing an anti-PD-1 drug called Pembrolizumab, which may have the potential to reduce the risk of melanoma recurrence after surgery.
See all of the clinical trials at Holden Comprehensive Cancer Center.
Our work is made possible in part by the support of donors through charitable giving. Friends of Holden Comprehensive Cancer Center can become partners in the effort to control and ultimately cure cancer. Learn how you can help us make a difference for cancer patients.
Skin cancer is the most common form of cancer. The most common warning sign of skin cancer is a change in the appearance of the skin, such as a new growth or a sore that will not heal. There are three main types of skin cancer:
We also treat a variety of other skin cancers with Mohs surgery, including adnexal carcinoma, atypical fibroxanthoma (AFX), dermatofibrosarcoma protuberans (DFSP), leiomyosarcoma, merkel cell carcinoma (MCC), extramammary Paget disease (EMPD), and microcystic adnexal carcinoma (MAC).
Treatment plans may include:
We bring experts from different fields of medicine to work together as a team called a multidisciplinary oncology group. Because many patients require more than one form of treatment, our team meets regularly to discuss the best course of treatment and works together to design the best personalized plan for every patient. The team, along with others on your care team, includes radiologists, medical oncologists, radiation oncologists, surgeons, social workers, pathologists, pharmacists, nurses, and laboratory-based scientists.
Our team of specialists focuses not just on skin cancer, but on your skin cancer. That means our team of experts will design a treatment plan that is tailored to your individual needs – we don’t believe in “one size fits all.” We will walk you through everything you need to know, including symptoms, treatments, and prognosis.